标题
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 5, Pages -
出版商
Oxford University Press (OUP)
发表日期
2016-10-05
DOI
10.1093/jnci/djw262
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
- (2016) Linda Mahjoubi et al. INVESTIGATIONAL NEW DRUGS
- Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma
- (2016) Meghan Shea et al. Journal of Thoracic Oncology
- Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
- (2016) Rebecca S. Heist et al. Journal of Thoracic Oncology
- The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC
- (2016) Si-Yang Liu et al. Journal of Thoracic Oncology
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- MET Exon 14 Skipping in Non-Small Cell Lung Cancer
- (2016) Rebecca S. Heist et al. ONCOLOGIST
- Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia
- (2015) Mary J. Gray et al. AMERICAN JOURNAL OF HUMAN GENETICS
- c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
- (2015) Aijun Shen et al. CANCER RESEARCH
- Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
- (2015) Russell W. Jenkins et al. Clinical Lung Cancer
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
- (2015) I. Watermann et al. Diagnostic Pathology
- MET-Mutated NSCLC with Major Response to Crizotinib
- (2015) Melody A. Mendenhall et al. Journal of Thoracic Oncology
- MET Mutation Associated with Responsiveness to Crizotinib
- (2015) Saiama N. Waqar et al. Journal of Thoracic Oncology
- Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
- (2015) Susan E. Jorge et al. LUNG CANCER
- MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor
- (2015) Yosuke Togashi et al. LUNG CANCER
- Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
- (2015) T. Sugano et al. MOLECULAR CANCER THERAPEUTICS
- A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells
- (2015) J Chakedis et al. ONCOGENE
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point
- (2015) Rachel B. Darman et al. Cell Reports
- Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung
- (2014) Thibault Vieira et al. LUNG CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
- (2013) Y. Zhang et al. CLINICAL CANCER RESEARCH
- Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes
- (2013) Mizuho Nakayama et al. CYTOKINE
- Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis
- (2013) Jiunn-Min Shieh et al. International Journal of Medical Sciences
- MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases
- (2013) Jennifer M. Boland et al. Journal of Thoracic Oncology
- Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity
- (2013) J Lefebvre et al. Cell Death & Disease
- Hepatocyte Growth Factor, a Determinant of Airspace Homeostasis in the Murine Lung
- (2013) Carla Calvi et al. PLoS Genetics
- Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
- (2012) J. M. Spoerke et al. CLINICAL CANCER RESEARCH
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- Met Kinase-dependent Loss of the E3 Ligase Cbl in Gastric Cancer
- (2012) Andrea Z. Lai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation
- (2012) Nathan V. Lee et al. PLoS One
- A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
- (2011) R. Tiedt et al. CANCER RESEARCH
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- A direct role for Met endocytosis in tumorigenesis
- (2011) Carine Joffre et al. NATURE CELL BIOLOGY
- The role of the c-Met pathway in lung cancer and the potential for targeted therapy
- (2011) Martin Sattler et al. Therapeutic Advances in Medical Oncology
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
- (2010) Yoshinari Asaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity
- (2010) J. W. Tyner et al. CANCER RESEARCH
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age: Figure 1.
- (2010) Stephen C. Kales et al. CANCER RESEARCH
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
- (2010) Yi-Hung Carol Tan et al. PLoS One
- Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage
- (2009) Julien Deheuninck et al. CELLULAR SIGNALLING
- Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
- (2009) S. Krishnaswamy et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now